MectaScrew Extension

K203335 · Medacta International S.A. · HWC · Feb 3, 2022 · Orthopedic

Device Facts

• Record ID: K203335
• Device Name: MectaScrew Extension
• Applicant: Medacta International S.A.
• Product Code: HWC · Orthopedic
• Decision Date: Feb 3, 2022
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3040
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

Reconstructive treatment of ruptured anterior and posterior cruciate ligaments by means of auto- and allografts.

Device Story

MectaScrew Extension is an implantable bone fixation fastener used in orthopedic surgery for tibial and femoral graft fixation during anterior and posterior cruciate ligament reconstruction. The device functions as an interference screw, providing mechanical fixation between a ligament graft and a bone tunnel. It is intended for use by surgeons in an operating room setting. The device is available in multiple configurations of diameter and length. It is designed to secure the graft to facilitate healing and joint stability.

Clinical Evidence

No clinical studies were conducted. Substantial equivalence is supported by non-clinical bench testing, including design validation, MR safety evaluation, torque resistance, pull-out strength, endurance properties regarding degradation, pyrogenicity testing (LAL and USP <151>), and biocompatibility assessment per ISO 10993.

Technological Characteristics

The device is a composite interference screw composed of RESOMER® Composite LR 706S B-TCP (70% RESOMER® LR 706 S and 30% B-TCP). It is available in diameters from 6 to 12 mm and lengths from 15 to 35 mm. Biocompatibility is evaluated per ISO 10993. Sterilization and packaging are consistent with predicate devices.

Indications for Use

Indicated for reconstructive treatment of ruptured anterior and posterior cruciate ligaments using auto- and allografts.

Regulatory Classification

Identification

A smooth or threaded metallic bone fixation fastener is a device intended to be implanted that consists of a stiff wire segment or rod made of alloys, such as cobalt-chromium-molybdenum and stainless steel, and that may be smooth on the outside, fully or partially threaded, straight or U-shaped; and may be either blunt pointed, sharp pointed, or have a formed, slotted head on the end. It may be used for fixation of bone fractures, for bone reconstructions, as a guide pin for insertion of other implants, or it may be implanted through the skin so that a pulling force (traction) may be applied to the skeletal system.

Predicate Devices

• KSEA Megafix-C Bioabsorbable Composite Interference Screw (K071437)
• MectaScrew PEEK (K190892)

Submission Summary (Full Text)

{0}------------------------------------------------

February 3, 2022

Image /page/0/Picture/1 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.

Medacta International SA % Chris Lussier Senior Director, Quality and Regulatory Medacta USA 3973 Delp Street Memphis, Tennessee 38118

### Re: K203335

Trade/Device Name: MectaScrew Extension Regulation Number: 21 CFR 888.3040 Regulation Name: Smooth Or Threaded Metallic Bone Fixation Fastener Regulatory Class: Class II Product Code: HWC Dated: January 3, 2022 Received: January 5, 2022

### Dear Chris Lussier:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

{1}------------------------------------------------

801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

for

Laura C. Rose, Ph.D. Assistant Director DHT6C: Division of Restorative, Repair and Trauma Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K203335

Device Name MectaScrew Extension

Indications for Use (Describe)

Reconstructive treatment of ruptured anterior and posterior cruciate ligaments by means of auto- and allografts.

Type of Use (Select one or both, as applicable)

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# 510(k) Summary

#### I. Submitter

Medacta International SA Strada Regina 6874 Castel San Pietro (CH) Switzerland Phone [phone] Fax [phone]

Contact Person: Stefano Baj, Regulatory and Compliance Director, Medacta International SA Applicant Correspondent: Chris Lussier, Senior Director of Quality and Regulatory, Medacta USA Date Prepared: November 12, 2020 Date Revised: February 2, 2022

#### II. Device

| Device Proprietary Name: | MectaScrew Extension |
|--------------------------|----------------------------------------------------|
| Common or Usual Name: | Screw, fixation, bone |
| Classification Name: | Smooth or threaded metallic bone fixation Fastener |
| Primary Product Code: | HWC |
| Regulation Number: | 21 CFR 888.3040 |
| Device Classification | II |

#### III. Predicate Device

Substantial equivalence is claimed to the following primary predicate device:

- KSEA Megafix-C Bioabsorbable Composite Interference Screw, K071437, Karl Storz A Endoscopy - America, Inc
Substantial equivalence is claimed to the following secondary predicate device:

- MectaScrew PEEK, K190892, Medacta International SA A
#### Device Description IV.

The MectaScrew Extension includes implantable devices used for the tibial and the femoral fixation of the graft in reconstructive treatment of knee ligament ruptures. They have been developed to provide interference between a ligament graft and a bone tunnel in the ligament reconstruction surgery.

The MectaScrew Extension implants includes MectaScrew C, a composite interference screw made of RESOMER® Composite LR 706S B-TCP, a mixture of 70 % RESOMER® LR 706 S and 30 % B-TCP.

{4}------------------------------------------------

MectaScrew C is available in 19 different configurations ranging from 6 to 12 mm in diameter and 15 to 35 mm in length.

#### V. Indications for Use

Reconstructive treatment of ruptured anterior and posterior cruciate ligaments by means of auto- and allografts.

#### VI. Comparison of Technological Characteristics

The MectaScrew Extension implants and the predicate device (K071437) share the following characteristics:

- shape ●
- materials;
- biocompatibility;
- device usage;
- sterility; and
- packaging.

The MectaScrew Extension implants differ from the predicate device (K071437) with respect to:

- . screw diameters;
- screw lengths; and
- driver connection. ●

#### VII. Performance Data

Based on the risk analysis, design validation and performance testing were conducted to written protocols. The following validation and tests are being provided in support of the substantial equivalence determination:

### Non-Clinical Studies

- DESIGN VALIDATION ●
- MectaScrew C Design Validation Report Test Report 48 according to Design Validation o Protocol M07.85.003 Nr. A8
- PERFORMANCE TESTING ●
- MR Safety evaluation Composite Interference Screw o

{5}------------------------------------------------

- Torque resistance of graft fixation device for ACL reconstruction: interference screw. O according to Test Protocol IL 07.09.485 Rev.2 and Empa Test Reports No. 5214022874 and 5214025594/1e
- Pull out strength of graft fixation device for ACL reconstruction: interference screw, o Rationale A3
- MectaScrew C Endurance properties with respect to the degradation phenomena, Rationale о A2
- PYROGENICITY ●
- o Bacterial endotoxin test (LAL test) according to European Pharmacopoeia §2.6.14 (which is equivalent to USP chapter <85>)
- 0 Pyrogen test according to USP chapter <151> for pyrogenicity determination
- o The subject devices are not labeled as non-pyrogenic or pyrogen free.
- BIOCOMPATIBILITY
- o Biocompatibility assessment as per ISO 10993 series and FDA Biocompatibility Guidance document Use of International Standard ISO 10993-1, Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process.

## Clinical Studies:

- No clinical studies were conducted. ●
## VIII. Conclusion

Based on the information provided within this submission, the MectaScrew Extension implants are substantially equivalent to the identified predicate devices. Substantial equivalence has been demonstrated through a comparison of intended use, design and technological characteristics, as well as performance evaluations.